Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Protara Therapeutics, Inc. (TARA) had Consolidated Net Income/Loss of $-17.31M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-17.31M |
|
-- |
|
-- |
|
$19.08M |
|
$-19.08M |
|
$1.77M |
|
$-17.31M |
|
$-17.31M |
|
$-17.31M |
|
$-17.31M |
|
|
Consolidated Net Income/Loss |
$-17.31M |
$-17.31M |
|
$-19.08M |
|
$-20.11M |
|
42.84M |
|
42.84M |
|
$-0.39 |
|
$-0.39 |
|
| Balance Sheet Financials | |
$159.50M |
|
$0.76M |
|
$49.96M |
|
$209.47M |
|
$10.94M |
|
-- |
|
$2.12M |
|
$13.06M |
|
$196.41M |
|
$196.41M |
|
$196.41M |
|
53.59M |
|
| Cash Flow Statement Financials | |
$-56.37M |
|
$-139.49M |
|
$82.72M |
|
$163.54M |
|
$50.40M |
|
$-113.14M |
|
$3.83M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.58 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-56.46M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.81% |
|
-8.81% |
|
-8.26% |
|
-8.81% |
|
$3.67 |
|
$-1.32 |
|
$-1.32 |
|